Nonmedical Switching in Rheumatic Disease: An Interview With Allan Gibofsky, MD
Allan Gibofsky, MD, shares insight on the cost associated with nonmedical switching in patients with rheumatic diseases.
EULAR 2018 Coverage
Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis
In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.
Sprifermin Improved Cartilage Morphology, Thickness in Knee Osteoarthritis
Sprifermin has a positive effect on cartilage morphology and cartilage thickness in radiographic knee osteoarthritis.
Allopurinol Medication Adherence Increased With Daily Text Message Reminders
Mobile phone text reminders could be an important tool to enhance medication adherence in people with gout.
Depressive Symptom Onset Linked to Disease Severity in Knee OA
To effectively treat individuals with radiographic knee OA and comorbid depressive disorder, it is necessary to use a combined treatment strategy of 2 interventions delivered in parallel to simultaneously target each condition.
RA Associated With Greater Reduction in Short-Term Disease Burden vs Osteoarthritis
Investigators analyzed MDHAQ/RAPID3 scores in patients with osteoarthritis or rheumatoid arthritis to assess disease burden associated with each rheumatic disease.
Optical Fiber Infrared Spectroscopy Identifies Septic vs Nonseptic Synovial Fluids
Researchers sought to confirm the interest of mid-infrared spectroscopy to discriminate synovial fluid samples from patients with septic arthritis from other causes of joint effusion.
Low Tuberculosis Screening Rates Observed Among Patients Starting TNFis
Only about half of patients who started TNFi therapy were screened for tuberculosis prior to therapy initiation.
SLE-DAS Superior to SLEDAI-2K in Detecting Changes in SLE Disease Activity
To assess validity of SLE-DAS, investigators performed a Spearman’s correlation between SLE-DAS, PGA, and SLEDAI-2K at the last follow-up visit.
Infliximab May Lower Glucocorticoid Requirements, Lead to Remission in Takayasu Arteritis
Treatment of active Takayasu arteritis with infliximab may result in remission or in a diminished requirement for glucocorticoids.
Want to read more?
Please login or register first to view this content.
Next post in EULAR 2018 Coverage
